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Background: Huachansu injection (HCS) is a water-soluble preparation made from Bufo gargarizans’s skin, which
has been widely used in clinics for tumor therapy in China. Though the anti-cancer activity of HCS has been verified
through studies in vitro and in vivo, there is little research about its potential anti-metastasis effect. The primary
objective of this study was to assess the effects of HCS on both the invasion of pancreatic cancer cells in vitro and
on the progression of liver metastasis in vivo in this study.
Methods: HCS anti-metastasis potential was accessed using both assay of Cell viability and invasion in vitro, and
then further Establishing xenograft model in nude mice. In the cell-based assay, mRNA and protein expression of
MMP-2, MMP-9 and VEGF was detected by semi-quantitative RT-PCR and western blotting. In animal experiment,
liver metastasis nodules and change of liver-body ratio was observed. Meanwhile, correlation of the CA19-9 and
CEA content in serum with the progression of liver metastasis was analyzed.
Result: We observed that HCS prevented the invasion of cancer cells, with inhibiting the expressions of MMP-2
and MMP-9, and reduced not only the number of metastasis nodules but the ratio of liver-body weight as well.
Furthermore, HCS decreased the expression of MMP-2, MMP-9 and VEGF in liver metastasis, while also reducing
CA19-9 contents in serum. In addition, correlation analysis indicated that the level of CA19-9 in serum was closely
related to the number of liver metastasis nodules.
Conclusion: Our experimental results suggest that HCS has some anti-metastasis potential to suppress the growth
of liver metastasis by decreasing the expression of MMP-2 and MMP-9 as well as VEGF.
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Pancreatic cancer has been considered an aggressive and
depressive malignancy with dismal survival rate [1]
because of early metastasis and delayed diagnosis, even
after optimal conventional therapy such as curative resec-
tion of the primary tumor, radiation and chemo-therapy
[2,3]. It is likely to metastasize early for this disease even
when small, except the cancer cells get generally its resist-
ance to chemotherapy and/or radiotherapy [4-6]. It was re-
ported that 80% of these patients had been already in local
infiltration and distant metastasis when diagnosed, among* Correspondence: llm101010@gmail.com
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unless otherwise stated.which the incidence of liver metastasis was more than 50%
[7,8]. In fact, Metastasis is considered as the primary cause
of death in patients with pancreatic carcinoma in recent
year [9]. For all these reasons, there has been calling for
novel agents and therapeutic strategies for this disease.
The detailed mechanisms of how pancreatic cancer cells
spread are poorly understood. However, behavior of malig-
nant cells is closely linked to changes in their microenvir-
onment [10], in which stroma is an important component
.In recent years, Importance of tumor stroma in facilitat-
ing tumor cell growth and invasion has been more clearly
defined [11]. Vascular endothelial growth factor (VEGF),
Matrix metalloproteinases (MMPs) including MMP-2 and
MMP-9 are abundant in the stroma around malignants is an Open Access article distributed under the terms of the Creative
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portant facilitators of cancer cell invasion in past stud-
ies by resolving basement membrane proteins,
Because of rich MMP-2 production found in the stro-
mal cells of pancreatic cancer [14] and the expression
of MMP-9 increasing in adjacent pancreatic cancer
cells [15]. VEGF is strongly induced by hypoxia form-
ing within the tumor microenvironment and VEGF
keeps not only its role as the most critical driver of
vascular formation but also stimulates the invasion
and metastasis of tumor cells [16,17].
HCS is a water-soluble preparation made from Bufo
gargarizans’s skin, which has been widely used in
China and other Asian countries in clinics for malig-
nant tumors [18,19]. So far, it has been verified that
HCS has significant anti-cancer effects in some gastro-
intestinal tumors such as hepatic, gastric, pancreatic
and esophageal carcinoma [20-23]. Experiment showed
that anti-tumor effects of HCS has been observed in
Human Pancreatic Cancer-cell mice, with the increase
in concentration of HCS, cell cycle was maintained at
the S-phase, with pRb protein expression upregulation
[24,25]. Recently, studies in clinic have suggested that
HCS alone or combined with other chemotherapeutic
agents, effectively improves the survival rate and the
quality of life for patients with gastrointestinal tumors
such as gallbladder, liver and pancreatic cancer
[26-28]. In addition, in a phase trials sponsored by our
department and M.D. Anderson Cancer Center, no
dose-limiting toxicity (DLT) was observed with the
use of HCS at doses up to 8 times higher than typic-
ally used in China and six patients had stable disease
prolonged or minor tumor shrinkage [29].
However, it has not been clarified whether HCS has
anti-metastasis effects on advanced pancreatic cancer.
The purpose of this study is to evaluate the anti-
metastasis activity of HCS and further to explore its
underlying anti-metastasis mechanisms.Methods
Cell lines and mice
Human pancreatic cancer cell lines SW1990, BxPC3 and
CF-PAC1 were obtained from the American Type Culture
Collection and grown in complete growth medium as rec-
ommended by the manufacturer. The cultured cells were
maintained in a humidified 5% CO2 atmosphere at 37.
Female BALB/c-nu/nu nude mice (18-22 g) were obtained
from Shanghai Laboratory Animal Center Chinese Acad-
emy of Sciences (Shanghai, China) and housed in laminar
flow cabinets under specific pathogen-free conditions with
food and water ad libitum. The study protocol was ap-
proved by the Shanghai Medical Experimental Animal
Care Committee.Drugs and reagents
HCS, prepared by concentrating the extraction of toad
skin 10 g to 1 ml, was obtained from Anhui Jinchan
Biochemical Co., Ltd. (Anhui, China). RPMI-1640 and
fetal bovine serum were purchased from Gibco (U.S.A).
VEGF monoclonal antibody was from BD Pharmingen
(U.S.A); MMP-9 and MMP-2 monoclonal antibody were
from Santa Cruz biotechnology, inc.(U.S.A). Cell counting
kit-8(CCK-8) was purchased from Dojindo, Molecular
Technologies, inc. (Gaithersburg, MD, U.S.A).
Cell viability assay
Briefly, cells were suspended at a final concentration of
5 × 103 cells/well and cultured in triplicate in a 96-well
microplate. After exposure to HCS, the viability of cells
was measured using the CCK-8 assay at 36 h, 48 h and
72 h. Then, CCK-8(10 μl) was added to each well con-
taining 100 μl mixture of culture medium and HCS (0,
0.156, 0.312, 0.625, 1.25, 2.50, 5.0 mg/ml, respectively).
The plate was incubated for 1 h at 37°C. Viable cells
were counted by absorbance measurements at 450 nm
using auto microplate reader (Tecan Sunrise, Austria).
The OD450 value was proportional to the viability of
cell. All experiments were performed in triplicate on
three separate occasions.
Cell invasion assay
Transwell chamber invasion assay was used to test the
effect of HCS on in vitro invasion of SW1990 cells ac-
cording to the manufacturer’s advice (BD Biosciences).
In brief, 500 μl of serum free media containing 1.0 × 105
SW1990 cells treated with or without HCS (10, 20 and
50ug/ml) were added into the upper chamber in dupli-
cate and allowed to invade toward the lower chamber
with 10% fetal bovine serum (FBS). After incubation for
24 hrs, the cells on the upper side of the chambers were
removed with a cotton swab and the cells on the lower
surface were fixed in 95% ethanol and stained with
0.1% crystal violet. Then, the transmigrated cells were
counted. For each experiment, 10 random high power
fields were chosen as described previously [30].
Reverse transcription polymerase chain reaction analysis
Total RNA was extracted by TRIzol reagent (Invitrogen,
San Diego, CA, USA) from SW1990 cells treated for
24 hr with HCS of 50ug/ml. 2 μg of purified total RNA was
used for reverse transcription PCR (RT-PCR) according to
the manufacturer’s instructions (MBI Fermentas, Vilnius,
Lithuania). Sequences of the PCR primers were: VEGF
forward 5′-CTACCTCCACCATGCCAAGT-3′, reverse
5′-TCTCTCCTATG TGCTGGCCT-3′; MMP-2 forward
5′-CAGGCTCTTCTCCTTTCACAAC-3′, reverse 5′-AA
GCCACG GCTTGGTTTTCCTC-3′; MMP-9 forward
5′-GGCGCTCATGTACCC TATGT-3′, reverse 5′-CTC
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GGGAGCCAAAAGGGT CATCATCTC-3′, reverse 5′-
CCATGCCAGTGAGCTTCCCGTTC-3′ chosen as an
internal control. We used Quantity-One Gel Imaging soft-
ware (BIO-RAD) to perform quantitative RT-PCR analyses
of mRNA levels, relative to GAPDH levels. All primers
were synthesized at Shanghai Sangon Biological Engineer-
ing & Technology Services Co (Shanghai, China).
Western blot analysis
After treatment with 50ug/ml HCS for 24 h, cells were
harvested and lysed in ice-cold NP40 lysis buffer with
protease inhibitor (0.5 mM phenylmethylsulfonyl fluor-
ide, PMSF) for 30 minutes on ice. Then the lysates were
centrifuged at 12,000 rpm for 15 minutes and the super-
natant was collected. Equal amounts of protein (30 μg)
were separated by 10% SDS-PAGE and then incubated
with anti-human monoclonal antibodies. Protein bands
were visualized by the enhanced chemiluminescence
(ECL) kit (Amersham Pharmacia Biotech, Uppsala,
Sweden). Images were analyzed with ImageJ software
supported by National Institute of Health (NIH).
Establishment of xenograft model in nude mice
6 × 106 in 0.2 mL of SW1990 cells in logarithmic phase
were inoculated into mice right armpit. Mice were sacri-
ficed and then the subcutaneous tumor was removed
when the tumor grew approximately 1000 mm3 in vol-
ume. The tumor tissue was sheared and then ground
into cell suspensions of 3 × 107/mL at final concentra-
tion in serum-free PBS (Phosphate Buffered Saline). Cell
viability greater than 95% was determined by trypan blue
exclusion. The mice were anesthetized with 10% chloral
hydrate and the spleen was exteriorized through a left
flank incision. 3 × 106 cells in 100 μL of suspensions
were slowly injected into the splenic pulp using an in-
oculating needle. The spleen was relocated into the ab-
dominal cavity and then the peritoneum and skin were
closed. All animals tolerated the procedure well.
Animal administration and assessment of liver metastasis
in vivo
A total of 27 mice with intrasplenic inoculation were
randomly divided into three groups a week later: Control
group administered with normal saline, HCS-L group
and HCS-H group administered with HCS at a dose of
1500 mg/Kg/day and 3000 mg/Kg/day separately. Each
group consisted of 9 mice. The daily experimental
dosage was calculated according to the following
human–mouse transfer formula: Db = Da × Rab, where
Da, Db and Rab represent human dosage (g/kg), mouse
dosage (g/kg), and conversion coefficient respectively.
The typical dose of HCS used for patients in China
is 10-15 g daily (approximately 7.5 g/m2). All micereceived intraperitoneal injection of 0.4 ml normal saline
or HCS each day after randomized division. Mice were
weighed each week. All experiments on mice were con-
ducted in accordance with the guidelines of the NIH for
the care and use of laboratory animals. Mice were sacri-
ficed six weeks after inoculation and then blood sam-
pling was collected through mouse eye’s blood vessel.
The blood samples were centrifuged and the serums
were collected for ELISA assay. The livers were excised
and weighed for assessing the ratio of liver to body
weight (g/100 g), and the metastases on the surface of
liver were enumerated by a dissecting microscope. Liver
metastases were placed in 10% neutral buffered formalin
for immunohistochemistry.
Immunohistochemical analysis
Liver metastases in 10% buffered formalin were dehy-
drated and embedded in paraffin. Dewaxed paraffin-
embedded sections measured 4 μm were immunostained
according to the protocol of streptavidin-peroxidase (SP)
kit (ZYMED, U.S.A). Immunoreactions were visualized
with HRP conjugated IgG (goat anti-rabbit/mouse anti-
body) and developed in diaminobenzidine. The sections
were counterstained with hematoxylin and permanently
mounted. The slides in 10 randomly selected high power
fields (HPF, 400×) were examined in a blinded fashion
with light microscopy by two independent researchers
[31]. ImageJ software was used to analyze the optical
density (OD) of positively-stained cells on the slides.
Enzyme-linked immunosorbent assay (ELISA) of serum
samples
Of the corresponding liver metastasis samples, carbohy-
drate antigen CA19-9 and carcinoembryonic antigen (CEA)
levels were measured using Human Immunoassay kits
(Calbiotech, CA, USA) in 19/27 serum samples available
from the mice with liver metastasis. Serum samples were
assayed in duplicate on two separate occasions with associ-
ated standards as controls in accordance with manufac-
turer’s recommendations.
Statistical analysis
Group differences were statistically analyzed using Stu-
dent’s t-test or One-way analysis of variance for unpaired
values, Mann-Whitney’s U test was used to analyze the
metastases in liver, Kruskal-Wallis test for the ratio of
liver to body weight, and Correlation of the CA19-9 and
CEA content in serum with the liver metastasis was
evaluated by Linear Regression test. The level of signifi-
cance was set at p < 0.05, and data are expressed as
mean ± standard deviation (SD). The statistical analysis
was performed using GraphPad prism version 5.01 soft-
ware (SanDiego, CA, USA).
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HCS inhibited pancreatic cells viability and the invasion of
SW1990 cells
To examine whether treatment with HCS influences
proliferation of tumor cells, we employed CCK-8 assays.
The cells of three cell lines (SW1990, BxPC3 and CF-
PAC1) were treated with HCS of different concentra-
tions (0.156, 0.312, 0.625, 1.25, 2.5 and 5.0 mg/ml). After
48 hours, cell growth was inhibited in all cell lines
(Figure 1A). Since there was no standard concentration
for the use of HCS in cell experiments, we used several
different concentrations mentioned above to test the ef-
fect of HCS on the growth of SW1990 cells at variousFigure 1 Inhibitory effects of HCS on the viability and invasive behav
pancreatic cancer cell lines (SW1990, BxPC3 and CF-PAC1) after 48 hours. (B
hours. (C) IC50=0.545mg/ml was calculated in the time-dose-curve at 48 h
the lower side of the chamber were stained with 1% crystal violet and cou
was reduced in a dose-dependent manner. (F-I) 24 hours after HCS (50μg/
reduced by 32.8±2.6% and 37.4±2.8% respectively (F,G); the protein expres
compared to the Control (P<0.05). Data are from three independent exper
statistically, compared to controls; “ns” presents no significant difference.time points (36, 48 and 72 h). The inhibition rate was
8%-75% at 36 h, 10%-86% at 48 h and 13%-96% at 72 h
respectively; The higher the concentration of HCS, the
better the effect of its inhibition (Figure 1B). The inhib-
ition effect of 0.156 mg/ml was not different among at
36 h, 48 h and 72 h (P > 0.05), but in other concentra-
tions we found the inhibition effect at 48 h was higher
than at 36 h (P < 0.05), 72 h higher than 48 h (P < 0.05),
Differences between two groups were evaluated by t-test
analysis. P < 0.05 was considered statistically significant.
We chose the IC50 value (50% inhibitory concentration)
at 48 h as the reference indicators in this experiment.
According to CCK-8 introduction, IC50 value (50%ior of pancreatic cancer cells. (A) Effects of HCS on proliferation of
) Effects of HCS on proliferation of SW1990 cells after 36, 48 and 72
our for SW1990. (D) After 24 hours of incubation, cells that migrated to
nted under a microscope. (E) The invasive capability of SW1990 cells
ml) treatment, the mRNA expression of MMP-2 and MMP-9 was
sion of decreased by 33.7±2.5% and 43.8±3.7% respectively (H,I), as
iments. In the bar graph, *: P<0.05 indicates the difference significant
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0.545 mg/ml at 48 h (Figure 1C).
In order to further determine the effect of HCS on the
invasive behavior of tumor cells, we adopted transwell
test. SW1990 cells with highly-metastatic potential were
treated with HCS of 0.01, 0.02 and 0.05 mg/ml respect-
ively. After 24 hours, HCS significantly inhibited the
invasion of SW1990 cells at the concentration of 0.02 mg/
ml and 0.05 mg/ml (P < 0.05), as compared with the con-
trol untreated (Figure 1D,E).
HCS reduced the expressions of MMP-2 and MMP-9 in
SW1990 cells in vitro
As is well known, MMP-2 and MMP-9 have been impli-
cated in metastasis and invasion of malignant tumor
cells [32]. Here, semi-quantitative RT-PCR and western
blotting were performed for MMP-2 and MMP-9 in
SW1990 cells. The bands of MMP-2 and MMP-9 at
mRNA and protein levels indicated significant difference
between the Control and HCS groups (Figure 1F,G,H,I).
The protein expression of MMP-2 and MMP-9 de-
creased by 33.7 ± 2.5% and 43.8 ± 3.7% respectively; the
mRNA expression of them reduced by 32.8 ± 2.6% and
37.4 ± 2.8% respectively in HCS-L/H groups, compared
to the Control (P < 0.05).
HCS inhibited the progression of liver metastasis in vivo
To further observe the effects of HCS on tumor metas-
tasis in vivo, we established an animal model with liverFigure 2 Effect of HCS on the liver metastases from human pancreati
HCS-treated groups was less than the Control (P = 0.042). (B) The ration of
the Control (P<0.01). (C) Livers with metastatic nodules in Control (8/9), HCmetastasis from human pancreatic cancer by SW1990
cells. After HCS treatment described above, experimen-
tal animals were weighed and then sacrificed. At the
same time, livers were excised and then weighed. We
identified liver metastases in 8 of 9 mice in Control-
group, 6 of 9 in HCS-L group and 5 of 9 in HCS-H
group respectively (Figure 2C). It was observed that
there was a dramatic reduction in the number of liver
metastases as well as in the ratio of liver to body weight
in the HCS-treated animals (Figure 2A,B). The average
number of metastatic tumors per liver was 35.7 ± 4.2,
19.4 ± 2.8 and 14.5 ± 2.3and the ratio of liver to body
weight was 4.64 ± 0.28 g/100 g, 3.72 ± 0.16 g/100 g and
3.53 ± 0.17 g/100 g (P < 0.05, seen in Additional file 1:
Table S1), corresponding to the Control, HCS-L and
HCS-H treated group respectively. All these evidences
indicated that HCS could inhibit the progression of liver
metastasis from pancreatic cancer.
HCS reduced the expressions of VEGF, MMP-2 and MMP-9
in metastasis in vivo
To determine the possible suppression pathway of HCS
to metastatic mechanism, we detected the expression of
VEGF, MMP-2 and MMP-9 in liver metastases using im-
munohistochemistry analysis. All immunostained tumor
sections were examined by bright-field microscopy and
photographed with a Nikon ECLIPSE E600 micros-
cope (Nikon, Japan) camera using 4×,10×, 20× and 40×
objective (Figure 3A,B). Images were loaded into thec cancer by SW1990 cells. (A) The number of liver metastases in
liver-body weight was decreased in HCS-treated groups, compared to
S-L (6/9) and HCS-H (5/9) groups.
Figure 3 Immunohistochemical analysis of VEGF, MMP-2 and MMP-9 expression in liver metastases. (A) H-E staining of liver metastasis
×4, 10, 20 magnification; (B) Detection for the expression of VEGF, MMP-2 and MMP-9 by streptavidin-peroxidase (SP) conjugated method, ×40
magnification; (C) With optical density analysis of liver tumor sections by ImageJ software, the expression of VEGF was reduced by 28.3±2.2%
and 63.2±5.7%, MMP-2 by 19.8±1.7% and 59.2±6.3% as well as MMP-9 by 25.7±2.4% and 50.1±5.2% in HCS-L and HCS-H groups respectively,
compared to the Control (P<0.05), by Mann–Whitney test. Data is mean±SD.
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described previously [33]. Densitometric analysis exhib-
ited that the expression of VEGF, MMP-2 and MMP-9
in liver metastases was reduced by 28.3%, 19.8% and
25.7% respectively in the HCS-L group, and decreased
by 63.2%, 59.2% and 50.1% separately in the HCS-H
group, as compared with the Control (Figure 3C).
HCS impacts on the concentration of CEA and CA19-9 in
serum
As is well known, CA19-9 is a very important prognostic
factor in pancreatic cancer. In this experiment, we de-
tected the concentration of CEA and CA19-9 in serum
by ELISA assay in 19 blood samples. The CA19-9 con-
centration in HCS-treated groups (mean was 281.5U/mlFigure 4 ELISA analysis for the concentration of CEA and CA19-9 in seru
HCS-treated groups differed significantly from that of the Control (P = 0.038); (B
Control and HCS groups (P>0.05), Data analyzed by Kruskal-Wallis test. (C) The li
decreased with the number of liver metastases reduced (R2 = 0.442, P = 0.0026and 262.8U/ml in HCS-L and HCS-H groups respect-
ively) differed significantly from that of the Control
(388.1U/ml) (Figure 4A; P = 0.038). Meanwhile, there
was not any dramatical difference in the contents of
serum CEA among three experimental groups, though
the CEA concentration was decreased in HCS groups
(Figure 4B; P > 0.05).
Correlation of the CA19-9 and CEA content in serum with
the progression of liver metastasis
Subsequently, we evaluated the relation between the
content of CA19-9, CEA in serum and the number of
liver metastatic nodules so as to observe the HCS influ-
ence on progression of advanced pancreatic cancer.
Linear regression analysis indicated that CA19-9 contentm after HCS treatment. (A) The CA19-9 concentrations in serum in
) The CEA concentrations were not different statistically among the
near regression analysis indicated that after HCS treatment, CA19-9 in serum
), but which was independent of CEA in serum (R2 = 0.001, P = 0.8899).
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nodules (R2 = 0.442, P = 0.0026), which was yet not
linked obviously with CEA content in serum (R2 = 0.001,
P = 0.8899) (Figure 4C).
Discussion
Pancreatic cancer remains an unfortunate disease with a
5-year survival rate below 6%, a worst survival in all can-
cers [34] for its early remote dissemination. This reflects
the inability of current systemic therapy to prevent or
treat pancreatic cancer metastases and underscores the
need for novel therapy.
The research of HCS has been going on in America,
China and some other Asian countries such as Japan
and Korea. Over recent years, HCS is gaining ever-
increasing attention due to its various biological activ-
ities displayed in therapy of many diseases [35,36]. In
this study, we tried to examine whether HCS had some
anti-metastasis effects on pancreatic cancer. In vitro
HCS evidently inhibited the invasion of SW1990 cells as
well as the cell viability of three cell lines (SW1990,
BxPC3 and CF-PAC1), and in vivo the number of liver
metastases was decreased, accompanied with the ratio of
liver-body weight improved by HCS in the nude mice
model. It means that HCS has the potential of anti-
metastasis effect on advanced pancreatic cancer.
Studies of matrix metalloproteases (MMPs) in invasive
cancers have indicated that MMPs play an important
role in the development of tumor metastases, among
which MMP-2 and MMP-9 are particularly associated
with distant dissemination of malignant tumors [37].
Moreover, some researches were reported that high ex-
pression of MMP-2 and MMP-9 was found in pancreatic
cancer [38,39]. Our findings showed that the expressions
of MMP-2 and MMP-9 at the levels of mRNA and pro-
tein were significantly down-regulated by HCS treat-
ment, indicating that HCS inhibited the growth of liver
metastasis possibly through decreasing the expression of
MMP-2 and MMP-9.
Angiogenesis depends on numerous activating factors
that were demonstrated to be over-expressed in pancre-
atic cancer, while it has been verified that VEGF is a key
inducer of angiogenesis. Over recent years, VEGF has
been targeted in clinic for treatment of some cancers
such as rectal cancer, lung cancer and liver cancer
[40-42]. In this experiment, HCS abated the expression
of VEGF in liver metastasis, which implied that maybe
there was some relationship between VEGF and MMPs in
the context of this experiment. This result was also con-
sistent with recent studies that MMPs enhanced tumor
angiogenesis by triggering the angiogenic switch [43].
As a prognostic marker, the serum CA19-9 has re-
placed CEA because it is more specific and sensitive for
pancreatic cancer [1,44]. In this experiment, the CA19-9content in serum declined obviously from 388.1U/ml in
the Control to 262.8-281.5U/ml in HCS-treated animals
(data not shown); however, the concentration of CEA in
serum changed little among the Control and HCS
groups. Incidentally, there was no dramatic difference in
terms of CA19-9 between the low and high doses of
HCS, corresponding to the results above that the num-
ber of liver metastases showed no difference between
HCS groups. Then, linear regression analysis indicated
that the change of CA19-9 was closely related with the
number of liver metastasis, which confirmed that CA19-
9 in serum reflected the progression of advanced pancre-
atic cancer with liver metastasis as a prognostic maker.
Conclusion
In this study, based on the present findings, we inferred
that HCS could inhibit the progression of advanced pan-
creatic cancer with liver metastasis through down-
regulating the expression of VEGF, MMP-2 and MMP-9.
Nevertheless, this experiment only throws some light on
the mechanism of HCS inhibitory effects on metastasis
and progression of advanced pancreatic cancer, and so
more researches should be pushed on in further studies.
Additional file
Additional file 1: Table S1. Effect of HCS treatment on the progression
of liver metastasis from advanced pancreatic cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JHY carried out animal and some cell experiment, prepared the manuscript.
LLM coordinated the study. XYZ carried out the experiments about IC50
calculation of HCS. WDS was involved in designing the experiments. All
authors read and approved the final manuscript.
Acknowledgements
This study was funded by TCM oncology department FuDanUniversity.
Author details
1Department of Oncology, Second TCM Hospital of Guang Dong province,
60 Heng Fu Road, Guang Zhou, Guang Dong province, China. 2Department
of Integrative Oncology, Cancer Hospital, Fudan University, 270 Dong An
Road, Shanghai 200032, China.
Received: 7 November 2013 Accepted: 30 September 2014
Published: 13 December 2014
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics,
2008. CA Cancer J Clin 2008, 58:71–96.
2. Lundin J, Roberts PJ, Kuusela P, Haglund C: The prognostic value of
preoperative serum levels of CA 19-9 and CEA in patients with
pancreatic cancer. Br J Cancer 1994, 69:515–519.
3. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA,
Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans
DB: Neoadjuvant chemoradiotherapy for adenocarcinoma of the
pancreas: treatment variables and survival duration. Ann Surg Oncol 2001,
8:123–132.
Yin et al. BMC Complementary and Alternative Medicine 2014, 14:483 Page 8 of 8
http://www.biomedcentral.com/1472-6882/14/4834. DiMagno EP, Reber HA, Tempero MA: AGA technical review on the
epidemiology, diagnosis, and treatment of pancreatic ductal
adenocarcinoma, American Gastroenterological Association.
Gastroenterology 1999, 117:1464–1484.
5. Sener SF, Fremgen A, Menck HR, Winchester DP: Pancreatic cancer: a
report of treatment and survival trends for 100,313 patients diagnosed
from 1985-1995, using the National Cancer Database. J Am Coll Surg
1999, 189:1–7.
6. Kornmann M, Beger HG, Link KH: Chemosensitivity testing and test-
directed chemotherapy in human pancreatic cancer. Recent Results Cancer
Res 2003, 161:180–195.
7. Fortner JG: Regional pancreatectomy for cancer of the pancreas, ampulla,
and other related sites. Tumor staging and results. Ann Surg 1984,
199:418–425.
8. Smeenk HG, Incrocci L, Kazemier G, van Dekken H, Tran KT, Jeekel J, van Eijck
CH: Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/
R-2 resections for pancreatic cancer. Dig Surg 2005, 22:321–328.
9. Stupack DG, Cheresh DA: ECM remodeling regulates angiogenesis:
endothelial integrins look for new ligands. Sci STKE 2002, 2002:e7.
10. Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer 2001,
1:46–54.
11. Bhowmick NA, Moses HL: Tumor-stroma interactions. Curr Opin Genet Dev
2005, 15:97–101.
12. Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T,
Kloppel G, Kalthoff H, Folsch UR, Schafer H: Tumor stroma interactions
induce chemoresistance in pancreatic ductal carcinoma cells involving
increased secretion and paracrine effects of nitric oxide and interleukin-
1beta. Cancer Res 2004, 64:1331–1337.
13. Teraoka H, Sawada T, Nishihara T, Yashiro M, Ohira M, Ishikawa T, Nishino H,
Hirakawa K: Enhanced VEGF production and decreased immunogenicity
induced by TGF-beta 1 promote liver metastasis of pancreatic cancer.
Br J Cancer 2001, 85:612–617.
14. Maatta M, Soini Y, Liakka A, Autio-Harmainen H: Differential expression of
matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP
in hepatocellular and pancreatic adenocarcinoma: implications for tumor
progression and clinical prognosis. Clin Cancer Res 2000, 6:2726–2734.
15. Qian X, Rothman VL, Nicosia RF, Tuszynski GP: Expression of
thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix
metalloproteinase-9 production. Pathol Oncol Res 2001, 7:251–259.
16. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF: The angiogenic
factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle
cell adhesion and stimulates chemotaxis through integrin alpha (6) beta
(1) and cell surface heparan sulfate proteoglycans. Endocrinology 2002,
143:1441–1450.
17. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF: CYR61, a product of a
growth factor-inducible immediate early gene, promotes angiogenesis
and tumor growth. Proc Natl Acad Sci U S A 1998, 95:6355–6360.
18. Chen KK, Kovarikova A: Pharmacology and toxicology of toad venom.
J Pharm Sci 1967, 56:1535–1541.
19. Zhang J, Sun Y, Liu JH, Yu BY, Xu Q: Microbial transformation of three
bufadienolides by Nocardia sp. and some insight for the cytotoxic
structure-activity relationship (SAR). Bioorg Med Chem Lett 2007,
17:6062–6065.
20. Gan T, Wu Z, Tian L, Wang Y: Chinese herbal medicines for induction of
remission in advanced or late gastric cancer. Cochrane Database Syst Rev
2010, 20(1):CD005096.
21. Chen Z, Zhai XF, Su YH, Wan XY, Li J, Xie JM, Gao B: Clinical observation of
cinobufacini injection used to treat moderate and advanced primary
liver cancer. Zhong Xi Yi Jie He Xue Bao 2003, 1:184–186.
22. Wang J, Jin Y, Xu Z, Zheng Z, Wan S: Involvement of caspase-3 activity
and survivin downregulation in cinobufocini-induced apoptosis in A 549
cells. Exp Biol Med (Maywood) 2009, 234:566–572.
23. Qi F, Li A, Inagaki Y, Xu H, Wang D, Cui X, Zhang L, Kokudo N, Du G, Tang W:
Induction of apoptosis by cinobufacini preparation through mitochondria-
and Fas-mediated caspase-dependent pathways in human hepatocellular
carcinoma cells. Food Chem Toxicol 2012, 50:295–302.
24. Xiao-yan Z, Zhi-qiang M, Zhen C, Jun-hua L, Ye-hua S, Wun A, Peng W,
Jian-qin H, Lu-ming L: Anti-tumor Effects ofD ifferentFractions from C
inobutacini in human pancreatic cancer-bearing SW1990 mice. SHJTCM
2009, 43:69–71.25. Xiao-yan Z, Lu-ming L, Zhen C, Jun-hua L, Li-tao X, Zhi-qiang M: Effects of
“Huachansu Injecion” combined with Gemcitabine on PANC-1 cell
proliferation and cell cycle. SHJTCM 2013, 47:85–88.
26. Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR: Efficacy and safety of
gemcitabine-oxaliplatin combined with huachansu in patients with advanced
gallbladder carcinoma. World J Gastroenterol 2008, 14:5210–5216.
27. Zuo X, Cui Y: Clinical research progress on the antitumor effects of
cinobufacini. China Clin Oncol 2003, 8:232–235.
28. Hai-tao D, Yong-he HE: Therapeutic effects of the combination of cinobufacini
injection and chemotherapy in big artery for 130 patients with middle and
late stages of pancrea cancer. China J New Drugs 2007, 16:1403–1405.
29. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L,
Thornton B, Chang DZ, Liao Z, Kurzrock R: Pilot study of huachansu in
patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or
pancreatic cancer. Cancer 2009, 115:5309–5318.
30. Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S,
Reiss M: Targeting endogenous transforming growth factor beta receptor
signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits
their invasive phenotype1. Cancer Res 2004, 64:5200–5211.
31. Juuti A, Lundin J, Nordling S, Louhimo J, Haglund C: Epithelial MMP-2
expression correlates with worse prognosis in pancreatic cancer.
Oncology 2006, 71:61–68.
32. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix
metalloproteinases: biologic activity and clinical implications. J Clin Oncol
2000, 18:1135–1149.
33. Ruifrok AC, Johnston DA: Quantification of histochemical staining by
color deconvolution. Anal Quant Cytol Histol 2001, 23:291–299.
34. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277–300.
35. Hong Z, Chan K, Yeung HW: Simultaneous determination of
bufadienolides in the traditional Chinese medicine preparation, liu-shen-
wan, by liquid chromatography. J Pharm Pharmacol 1992, 44:1023–1026.
36. Bick RJ, Poindexter BJ, Sweney RR, Dasgupta A: Effects of Chan Su, a
traditional Chinese medicine, on the calcium transients of isolated
cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking.
Life Sci 2002, 72:699–709.
37. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis.
Cancer Chemother Pharmacol 1999, 43(Suppl):S42–S51.
38. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G: Expression
and in-situ localization of genes coding for extracellular matrix proteins
and extracellular matrix degrading proteases in pancreatic cancer. Int J
Cancer 1995, 62:407–413.
39. Nagakawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y: Histologic features of
venous invasion, expression of vascular endothelial growth factor and
matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation
with liver metastasis in pancreatic cancer. Pancreas 2002, 24:169–178.
40. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV,
Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG,
Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW,
Jain RK: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab,
radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary
phase II study. J Clin Oncol 2009, 27:3020–3026.
41. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R,
Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-
small-cell lung cancer. N Engl J Med 2006, 355:2542–2550.
42. Salmon JS, Lockhart AC, Berlin J: Anti-angiogenic treatment of
gastrointestinal malignancies. Cancer Invest 2005, 23:712–726.
43. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K,
Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9
triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000,
2:737–744.
44. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK: Evaluation
of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
Ann Intern Med 1989, 110:704–709.
doi:10.1186/1472-6882-14-483
Cite this article as: Yin et al.: Huachansu injection inhibits metastasis of
pancreatic cancer in mice model of human tumor xenograft. BMC
Complementary and Alternative Medicine 2014 14:483.
